Results from a new study in JAMA found that the Million Hearts Model, which paid participating health care organizations to assess and reduce patients’ CVD risk, decreased myocardial infarction and stroke rates for Medicare fee-for-service beneficiaries aged 40 to 79 years at high or medium risk for these events.

Trending Topics

Effective immediately, FDA has changed the labels on two medications used to bring down LDL cholesterol levels: bempedoic acid (Nexletol) and bempedoic acid/ezetimibe (Nexlizet).

A growing body of literature supports the essential role of the pharmacist in CV risk reduction. A recent 2023 analysis published in JAMA Network Open found that pharmacist-led interventions could prevent 15 million heart attacks in America and save more than a trillion dollars for the health care system over 30 years.

Kristin Wiisanen PharmD, FAPhA, FCCP, Pharmacy Today editor in chief

The utility of cystatin C—a protein biomarker similar to creatinine—has often been overlooked in routine practice as an alternative measurement of estimated glomerular filtration rate (eGFR) in patients with kidney disease.

Corey Diamond, PharmD

Pulse oximeters send beams of light through the skin to measure the amount of oxygen in the blood. Health care providers who rely on the technology have long known that the tool can yield inaccurate readings for people with darker skin.

Sonya Collins

APhA Member News

Crossword Challenge